Enfortumab vedotin and pembrolizumab (EVP) outcomes in patients (pts) with advanced urothelial carcinoma (aUC) and FGFR3 alterations: UNITE study analysis.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Elise Y. Cai, Li Zhang, Kevin R. Reyes, Zachariah Thomas, Cindy Y. Jiang, Eugene Oh, Tanya Jindal, Jeffrey Yinhong Zhong, Salvador Jaime-Casas, Catherine Fahey, Shilpa Gupta, Sumit Shah, Arnab Basu, Petros Grivas, Abhishek Tripathi, Jason Robert Brown, Omar Alhalabi, Irene Tsung, Matthew T. Campbell, Vadim S. Koshkin
Institutions: University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, The University of Texas MD Anderson Cancer Center, University of Michigan, Case Western Reserve University, City Of Hope National Medical Center, University of North Carolina at Chapel Hill, Cleveland Clinic, Stanford Medicine, Stanford University, University of Alabama at Birmingham, University of Washington, Fred Hutch Cancer Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7133219004
Cites:
Cited by:
Related to: